Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8542674 | 1.00 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2TOP2A | |
| SCHEMBL20691932 | 0.90 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2TOP2A | |
| SCHEMBL9309383 | 0.89 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2BACE1 | |
| SCHEMBL9309459 | 0.84 | SMYD2 (0.42) | SMYD2CYP3A4HTTSMN1; SMN2TOP2A | |
| SCHEMBL15685350 | 0.79 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2TOP2A | |
| SCHEMBL30941702 | 0.79 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2TOP2A | |
| SCHEMBL14328916 | 0.79 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2TOP2A | |
| SCHEMBL14321101 | 0.79 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2TOP2A | |
| SCHEMBL19714927 | 0.78 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2TOP2A | |
| SCHEMBL16569499 | 0.78 | SMYD2 (0.42) | SMYD2CYP3A4HTTSMN1; SMN2TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
| EP-0358154-B1 | Novel cyclobutane derivative and process for producing same | NIPPON KAYAKU KK (JP) | 1998-12-02 | — | — | EP | disclosed |
| US-5374625-A | Bis/hydroxymethyl/cycloalkyl derivatives; viricides | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1994-12-20 | — | — | US | disclosed |
| EP-0468352-A2 | Novel nucleic acid derivatives | Nippon Kayaku Kabushiki Kaisha (JP) | 1992-01-29 | — | — | EP | disclosed |
| WO-1990005730-A2 | NOVEL CYCLOBUTANE DERIVATIVE AND PROCESS FOR PRODUCING SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1990-05-31 | — | — | WO | disclosed |
| EP-0358154-A2 | Novel cyclobutane derivative and process for producing same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1990-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | SMYD2 1852/4885CYP3A4 3633/4885HTT 2382/4885 |
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | SMYD2 1852/4885CYP3A4 3633/4885HTT 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.